TY - JOUR
T1 - Should We Delay the Second COVID-19 Vaccine Dose in Order to Optimize Rollout?
T2 - A Mathematical Perspective
AU - Berkane, Soulaimane
AU - Harizi, Intissar
AU - Tayebi, Abdelhamid
AU - Silverman, Michael S
AU - Stranges, Saverio
N1 - Funding
This research work is supported by the National Research Council of Canada, under the grants NSERC-DG RGPIN-2020-04759 and NSERC-DG RGPIN-2020-0627. Our thought are with those who lost their loved ones in this pandemic, and our gratitude and respects go to all the front-line workers across Canada and worldwide for keeping us safe and keeping the world running.
Copyright © 2022 Berkane, Harizi, Tayebi, Silverman and Stranges.
PY - 2021/1/24
Y1 - 2021/1/24
N2 - Objectives: With vaccination shortage persisting in many countries, adopting an optimal vaccination program is of crucial importance. Given the slow pace of vaccination campaigns globally, a very relevant and burning public health question is whether it is better to delay the second COVID-19 vaccine shot until all priority group people have received at least one shot. Currently, many countries are looking to administer a third dose (booster shot), which raises the question of how to distribute the available daily doses to maximize the effectively vaccinated population. Methods: We formulate a generalized optimization problem with a total of u T = ∑ i = 1 n u i vaccine doses, that have to be optimally distributed between n different sub-populations, where sub-population u i represents people receiving the ith dose of the vaccine with efficacy α i . The particular case where n = 2 is solved first, followed by the general case of n dose regimen. Results: In the case of a two dose regimen, if the efficacy of the second dose is less than (or equal to) twice the efficacy of the first dose, the optimal strategy to maximize the number of effectively vaccinated people is to delay the second vaccine as much as possible. Otherwise, the optimal strategy would consist of administering the second dose as quickly as possible. In the general case, the optimal vaccination strategy would be to administer the k - th dose corresponding to the index providing the maximum inter-dose efficacy difference (α i - α i-1) for all possible values of i ∈ {1, … , n}, with α 0 = 0. Conclusion: Our results suggest that although extending the interval between doses beyond 12 weeks was likely optimal earlier in the pandemic, the reduced single dose efficacy of vaccines against the delta variant make this approach no longer viable.
AB - Objectives: With vaccination shortage persisting in many countries, adopting an optimal vaccination program is of crucial importance. Given the slow pace of vaccination campaigns globally, a very relevant and burning public health question is whether it is better to delay the second COVID-19 vaccine shot until all priority group people have received at least one shot. Currently, many countries are looking to administer a third dose (booster shot), which raises the question of how to distribute the available daily doses to maximize the effectively vaccinated population. Methods: We formulate a generalized optimization problem with a total of u T = ∑ i = 1 n u i vaccine doses, that have to be optimally distributed between n different sub-populations, where sub-population u i represents people receiving the ith dose of the vaccine with efficacy α i . The particular case where n = 2 is solved first, followed by the general case of n dose regimen. Results: In the case of a two dose regimen, if the efficacy of the second dose is less than (or equal to) twice the efficacy of the first dose, the optimal strategy to maximize the number of effectively vaccinated people is to delay the second vaccine as much as possible. Otherwise, the optimal strategy would consist of administering the second dose as quickly as possible. In the general case, the optimal vaccination strategy would be to administer the k - th dose corresponding to the index providing the maximum inter-dose efficacy difference (α i - α i-1) for all possible values of i ∈ {1, … , n}, with α 0 = 0. Conclusion: Our results suggest that although extending the interval between doses beyond 12 weeks was likely optimal earlier in the pandemic, the reduced single dose efficacy of vaccines against the delta variant make this approach no longer viable.
KW - COVID-19
KW - COVID-19 Vaccines
KW - Humans
KW - SARS-CoV-2
KW - Vaccination
UR - https://pubmed.ncbi.nlm.nih.gov/35140580
U2 - 10.3389/ijph.2021.1604312
DO - 10.3389/ijph.2021.1604312
M3 - Article
C2 - 35140580
SN - 1661-8556
VL - 66
SP - 1604312
JO - International Journal of Public Health
JF - International Journal of Public Health
ER -